A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
Clinical trial NCT07601620 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07601620
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-03
- Primary completion
- 2027-04-23
- Enrollment
- 258
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.